Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | VNN1 | O95497 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23879203 | 0.89 | LOXL2 (0.71) | LOXL2MAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL12880486 | 0.84 | LOXL2 (0.46) | LOXL2LMNAMAOAMAOBVNN1 | |
| SCHEMBL1796909 | 0.82 | LMNA (0.77) | LOXL2LMNACHRM2KDM4EALDH1A1 | |
| SCHEMBL184001 | 0.82 | LMNA (0.77) | LOXL2LMNACHRM2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1169438 | 0.82 | LOXL2 (0.45) | LOXL2LMNAMAOAMAOBVNN1 | |
| SCHEMBL8897410 | 0.82 | LOXL2 (0.61) | LOXL2MAOAMAOBKDM4EMEN1 | |
| SCHEMBL29912750 | 0.81 | LOXL2 (0.65) | LOXL2MAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL7935598 | 0.81 | MAOA (0.61) | LOXL2MAOAMAOBVNN1KDM4E | |
| Hydrochloric Acid SCHEMBL6077029 | 0.80 | LMNA (0.74) | LMNACHRM2KDM4EALDH1A1MEN1 | |
| SCHEMBL6396768 | 0.80 | LOXL2 (0.59) | LOXL2LMNAMAOAMAOBCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220290140-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | BIOGEN MA INC. | 2022-09-15 | — | — | US | disclosed |
| US-20220290140-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | BIOGEN MA INC. | 2022-09-15 | — | — | US | disclosed |
| EP-4017545-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | Biogen MA Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021034924-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | BIOGEN MA INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021034924-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | BIOGEN MA INC. (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220290140-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | TK1, TTR, TALDO1 | LOXL2 2901/4885LMNA 2483/4885MAOA 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.